Teva Pharmaceutical Industries Ltd (TA:TEVA) — Stock Price
Teva Pharmaceutical Industries Ltd (TA:TEVA) is currently trading at ILA12050.00 ILA, down 0.08% today. Over the past 52 weeks, shares have ranged between ILA6211.00 and ILA12060.00. This page tracks Teva Pharmaceutical Industries Ltd's live share price on the TA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Teva Pharmaceutical Industries Ltd (TEVA) market capitalisation.
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Teva Pharmaceutical Industries Ltd's daily closing share price and trading volume on the TA exchange over the past year, giving a clear view of recent price momentum and liquidity.
Teva Pharmaceutical Industries Ltd Income Statement — Revenue, Profit & Earnings by Year
Teva Pharmaceutical Industries Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | ILA18.68 Billion | ILA16.54 Billion | ILA15.85 Billion | ILA14.93 Billion | ILA15.88 Billion |
| Cost of Revenue | ILA9.05 Billion | ILA8.48 Billion | ILA8.20 Billion | ILA7.95 Billion | ILA8.28 Billion |
| Gross Profit | ILA9.63 Billion | ILA8.06 Billion | ILA7.65 Billion | ILA6.97 Billion | ILA7.59 Billion |
| Research & Development | ILA1.10 Billion | ILA998.00 Million | ILA1.04 Billion | ILA838.00 Million | ILA967.00 Million |
| SG&A | ILA1.29 Billion | ILA1.16 Billion | ILA1.16 Billion | ILA1.18 Billion | ILA1.10 Billion |
| Total Operating Expenses | ILA5.35 Billion | ILA8.37 Billion | ILA7.21 Billion | ILA4.28 Billion | ILA4.50 Billion |
| Operating Income | ILA4.28 Billion | ILA-303.00 Million | ILA433.00 Million | ILA-2.10 Billion | ILA1.72 Billion |
| EBITDA | ILA3.42 Billion | ILA777.00 Million | ILA1.56 Billion | ILA-925.00 Million | ILA2.88 Billion |
| EBIT | ILA2.34 Billion | ILA-282.00 Million | ILA405.00 Million | ILA-2.23 Billion | ILA1.55 Billion |
| Interest Expense | ILA1.01 Billion | ILA1.00 Billion | ILA1.03 Billion | ILA966.00 Million | ILA1.06 Billion |
| Income Before Tax | ILA1.34 Billion | ILA-1.28 Billion | ILA-622.00 Million | ILA-3.06 Billion | ILA658.00 Million |
| Income Tax Expense | ILA-194.84 Million | ILA676.00 Million | ILA-7.00 Million | ILA-638.00 Million | ILA211.00 Million |
| Net Income | ILA1.53 Billion | ILA-1.64 Billion | ILA-559.00 Million | ILA-2.35 Billion | ILA417.00 Million |
Teva Pharmaceutical Industries Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Teva Pharmaceutical Industries Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | ILA40.76 Billion | ILA39.33 Billion | ILA43.48 Billion | ILA44.01 Billion | ILA47.67 Billion |
| Total Current Assets | ILA13.95 Billion | ILA12.55 Billion | ILA12.48 Billion | ILA12.05 Billion | ILA12.57 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | ILA3.71 Billion | ILA3.06 Billion | ILA3.41 Billion | ILA3.70 Billion | ILA4.53 Billion |
| Inventory | ILA3.18 Billion | ILA3.01 Billion | ILA4.02 Billion | ILA3.83 Billion | ILA3.82 Billion |
| Property, Plant & Equipment | — | — | — | ILA6.16 Billion | ILA6.48 Billion |
| Goodwill | ILA16.00 Billion | ILA15.15 Billion | ILA17.18 Billion | ILA17.63 Billion | ILA20.04 Billion |
| Total Liabilities | ILA32.84 Billion | ILA33.61 Billion | ILA35.35 Billion | ILA35.31 Billion | ILA36.42 Billion |
| Total Current Liabilities | ILA13.46 Billion | ILA12.80 Billion | ILA12.25 Billion | ILA11.47 Billion | ILA11.03 Billion |
| Long-term Debt | ILA14.99 Billion | ILA16.00 Billion | ILA18.16 Billion | ILA19.10 Billion | ILA21.62 Billion |
| Net Debt | ILA13.83 Billion | ILA14.78 Billion | ILA16.93 Billion | ILA18.76 Billion | ILA21.29 Billion |
| Total Stockholder Equity | ILA7.91 Billion | ILA5.37 Billion | ILA7.51 Billion | ILA7.90 Billion | ILA10.28 Billion |
| Retained Earnings | ILA-13.76 Billion | ILA-15.17 Billion | ILA-13.53 Billion | ILA-12.88 Billion | ILA-10.53 Billion |
Teva Pharmaceutical Industries Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Teva Pharmaceutical Industries Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ILA3.10 Billion | ILA1.25 Billion | ILA1.37 Billion | ILA1.59 Billion | ILA798.00 Million |
| Capital Expenditures | ILA542.32 Million | ILA498.00 Million | ILA526.00 Million | ILA548.00 Million | ILA562.00 Million |
| Free Cash Flow | ILA2.56 Billion | ILA749.00 Million | ILA842.00 Million | ILA1.04 Billion | ILA236.00 Million |
| Investing Cash Flow | ILA-557.47 Million | ILA792.00 Million | ILA968.00 Million | ILA656.00 Million | ILA1.52 Billion |
| Financing Cash Flow | ILA-2.29 Billion | ILA-1.79 Billion | ILA-1.91 Billion | ILA-1.49 Billion | ILA-2.17 Billion |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | ILA157.00 Million | ILA123.00 Million | ILA121.00 Million | ILA124.00 Million | ILA119.00 Million |
| Depreciation | ILA1.08 Billion | ILA1.06 Billion | ILA1.15 Billion | ILA1.31 Billion | ILA1.33 Billion |
| Change in Cash | ILA-216.77 Million | ILA73.00 Million | ILA393.00 Million | ILA636.00 Million | ILA21.00 Million |
Teva Pharmaceutical Industries Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Teva Pharmaceutical Industries Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 04, 2026 | — | — | — |
| Jul 29, 2026 | — | — | — |
| Apr 29, 2026 | — | — | — |
| Jan 28, 2026 | — | — | — |
| Nov 05, 2025 | — | — | — |
| Jul 30, 2025 | — | — | — |
| May 07, 2025 | 0.52 | 0.48 | +8.33% |
| Jan 29, 2025 | 0.71 | 0.68 | +4.41% |